Abstract
Prion diseases are fatal neurodegenerative disorders with no effective therapy. A hallmark of prion disease is the conversion of the normal cellular form of prion protein PrPC into a disease-associated isoform PrPSc. The authors recently have shown that a tyrosine kinase inhibitor, imatinib mesylate, induces clearance of PrPSc via specific inhibition of c-Abl in prion-infected cell culture models. In this study, the authors assessed the in vivo effects of imatinib mesylate on prion disease using a scrapie-infected mouse model and further investigated prion infectivity of the drug-treated scrapie-infected neuroblastoma (ScN2a) cells. The authors found that imatinib mesylate abolished prion infectivity to almost undetectable level in ScN2a cells and the level of PrPSc was significantly decreased by the drug in scrapie-infected mouse spleens as well as in ScN2a cells. Moreover, the drug treatment at an early phase of peripheral scrapie infection delayed the appearance of PrPSc in the central nervous system (CNS) and onset of clinical disease in mice. However, neither intraperitoneal nor intracerebroventricular delivery of the drug exerted any PrPSc clearance effect in the CNS.
This work was supported by the Bavarian research cooperation (FORPRION) granted by the Ministry of Science, Research and Art of Bavaria. E.F. is supported by the Emmy-Noether program of the German Research Foundation. The authors thank Nele Lindner for her excellent technical assistance, C. Weissmann for tga20 mice, and A. Aguzzi for XN antiserum.